dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Rodríguez-Otero, Paula |
dc.contributor.author | Mateos, María-Victoria |
dc.contributor.author | Martinez-Lopez, Joaquin |
dc.contributor.author | Hernández, Miguel-Teodoro |
dc.contributor.author | Ocio, Enrique M |
dc.contributor.author | Gironella Mesa, Mercedes |
dc.contributor.author | Rosiñol, Laura |
dc.date.accessioned | 2019-05-07T11:40:07Z |
dc.date.available | 2019-05-07T11:40:07Z |
dc.date.issued | 2019-03-18 |
dc.identifier.citation | Rodríguez-Otero P, Mateos MV, Martínez-López J, Hernández M-T, Ocio EM, Rosiñol L, et al. Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature. Blood Cancer J. 2019 ;9(4):36. |
dc.identifier.issn | 2044-5385 |
dc.identifier.uri | https://hdl.handle.net/11351/4062 |
dc.description | Disease control; Multiple myeloma; Biomarkers |
dc.description.abstract | Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. Among the 435 patients included in this post-hoc study, 18.6% remained alive and progression free after 5 years of treatment initiation. In these patients, overall survival (OS) rate at 10 years was 60.8% as compared with 11.8% for those progressing within the first 5 years. Hemoglobin (Hb) ≥ 12 g/dl (OR 2.74, p = 0.001) and MGUS-like profile (OR 4.18, p = 0.005) were the two baseline variables associated with long-term disease-free survival. Upon including depth of response (and MRD), Hb ≥ 12 g/dl (OR 2.27) and MGUS-like signature (OR 7.48) retained their predictive value along with MRD negativity (OR 5.18). This study shows that despite the use of novel agents, the probability of disease control at 5 years is still restricted to a small fraction (18.6%) of elderly MM patients. Since this endpoint is associated with higher rates of OS, this study provides important information about diagnostic and post-treatment biomarkers helpful in predicting the likelihood of disease control at 5 years. |
dc.language.iso | eng |
dc.publisher | Springer Nature |
dc.relation.ispartofseries | Blood Cancer Journal;9(4) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Mieloma múltiple - Prognosi |
dc.subject | Marcadors bioquímics |
dc.subject | Persones grans |
dc.subject.mesh | Multiple Myeloma |
dc.subject.mesh | /prevention & control |
dc.subject.mesh | Biomarkers |
dc.subject.mesh | Aged |
dc.title | Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41408-019-0176-x |
dc.subject.decs | mieloma múltiple |
dc.subject.decs | /prevención & control |
dc.subject.decs | biomarcadores |
dc.subject.decs | anciano |
dc.relation.publishversion | https://www.nature.com/articles/s41408-019-0176-x |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Rodríguez-Otero P] Clínica Universidad de Navarra, Pamplona, Spain. [Mateos MV, Ocio EM] Complejo Asistencial Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain. [Martínez-López J] Hospital Universitario 12 de Octubre, Instituto de Investigación 12 de Octubre, Madrid, Spain. [Hernández MT] Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. [Rosiñol L] Hospital Clinic I Provincial, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. [Gironella M] Hospital Universitari Vall d'Hebron, Barcelona, Spain. |
dc.identifier.pmid | 30886139 |
dc.identifier.wos | WOS:000462349100002 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |